The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer

Figures & data

Table 1. The clinical characteristics of patients with Stage III nonsmall cell lung cancer.

	All n = 56	Low-PNI n = 28	High-PNI n = 28	p-Value
Gender
Male/female	47/9	25/3	22/6	0.469
Age
Median (range), years	70 (41–84)	72 (64–79)	67 (41–84)	0.009*
Smoking status
Never/ever or current	5/51	0/28	5/23	0.051
ECOG-PS
0/1	44/12	18/10	26/2	0.020*
Stage
IIIA/IIIB/IIIC	22/30/4	8/18/2	14/12/2	0.259
Pathology
Adenocarcinoma/Squamous/others	23/28/5	8/18/2	15/10/3	0.113
Chemotherapy
Carboplatin/Cisplatin	49/7	25/3	24/4	0.999
PD-L1 expression
1%</1%–49%/≤50%	12/19/17	8/11/6	4/8/11	0.221

ECOG-PS: Eastern Cooperative Oncology Group performance status; PD-L1: programmed cell death 1 - ligand 1; PNI: prognostic nutritional index.

*p-Values < 0.05.

Table 2. Univariate analysis of several parameters as predictors of PFS and OS in patients with stage III NSCLC.

		PFS			OS
		HR	95% CI	p-Value	HR	95% CI	p-Value
Age	70</≤70	1.319	0.667–2.604	0.425	1.872	0.749–4.674	0.179
Gender	Male/Female	1.128	0.435–2.918	0.805	4.745	0.625–36.010	0.132
ECOG-PS	0/1	2.048	0.950–4.415	0.067	4.331	1.558–12.040	0.004*
Smoking	never/ever	0.992	0.301–3.268	0.990	3.800	0.495–29.150	0.199
Pathology	Non squamous/Squamous	1.963	0.926–4.160	0.078	3.402	1.12–10.331	0.031*
Stage	IIIA/IIIB/IIIC	0.953	0.552–1.645	0.862	1.230	0.597–2.531	0.574
Chemotherapy	Carboplatin/Cisplatin	0.761	0.267–2.166	0.608	0.681	0.156–2.971	0.609
PD-L1 expression	1%</1%–49%/≤50%	0.682	0.436–1.067	0.093	0.452	0.238–0.860	0.015*
PNI	37.9</≤37.9	0.459	0.229–0.919	0.027*	0.187	0.066–0.529	0.001*

ECOG-PS: Eastern Cooperative Oncology Group performance status; PD-L1: programmed cell death 1 – ligand 1; PNI: prognostic nutritional index; HR: hazard ratio; PFS: progressive free survival; OS: overall survival.

*p-Values < 0.05.

Table 3. Multivariate analysis for parameters as predictors of PFS and OS in patients with stage III NSCLC.

		PFS			OS
		HR	95% CI	p-Value	HR	95% CI	p-Value
ECOG-PS	0/1	2.483	0.882–6.989	0.084	2.672	0.756–9.442	0.127
Pathology	Non squamous/Squamous	1.657	0.679–4.039	0.265	3.290	0.810–13.360	0.095
PD-L1 expression	1%</1%–49%/≤50%	0.940	0.241–1.298	0.176	1.105	0.504–2.423	0.803
PNI	37.9</≤37.9	0.559	0.241–1.298	0.176	0.187	0.046–0.760	0.019*

ECOG-PS: Eastern Cooperative Oncology Group performance status; PD-L1: programmed cell death 1 - ligand 1; PNI: prognostic nutritional index; HR: hazard ratio; PFS: progressive free survival; OS: overall survival.

*p-Values < 0.05.

Figure 1. PNI ROC curves analysis for OS in stage III NSCLC patients. ROC: receiver operating characteristic; PNI: prognostic nutritional index; OS: overall survival; NSCLC: non-small cell lung cancer.

Figure 2. Based on PNI, a Kaplan–Meier curve analysis of PFS and OS for 56 NSCLC patients treated with durvalumab after chemoradiation therapy was performed. (A) PFS based on PNI. (B) OS based on PNI. PFS: progressive free survival; OS: overall survival; PNI: prognostic nutritional index; NSCLC: non-small cell lung cancer.

Data availability statement

The datasets used and analyzed during the current study are available from the corresponding author on a reasonable request.